GP369, an FGFR2-IIIb specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling

Study defines an FGF receptor 2 isoform as a key player in human tumorigenesis, also offering preclinical proof-of-concept for the beneficial use of FGFR2 antibodies in cancer treatment.